Nivolumab + Relatlimab: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Nivolumab + Relatlimab

• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 211 locations
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
  NCT05428007 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 4 locations
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
  NCT04697576 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
  NCT06295159 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 244 locations
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 81 locations

Common questions

How many recruiting trials involve Nivolumab + Relatlimab?

6 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.